WEED, INC.
For the period ended Mar 31, 2026. Filed May 15, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 15, 2026
BUDZStored price and day change unavailable
What changed in Management’s Discussion and Analysis?
Read the current filingPrevious report: 10-Q
Period ended 2025-09-30; filed 2025-12-23.
0001096906-25-002153
ITEM 2. Management’s Discussion and Analysis of Financial Condition and Results of OperationsCurrent report: 10-Q
Period ended 2026-03-31; filed 2026-05-15.
0001096906-26-000814
ITEM 2. Management’s Discussion and Analysis of Financial Condition and Results of OperationsThe baseline is this issuer’s latest earlier reporting period of the same form that was filed before the current report. A previous 10-Q is a different quarter, not a year-over-year comparison. Amendments are excluded.
Compared 65 previous paragraphs and 51 current paragraphs.
27 unchanged; 14 reworded; 10 added; 19 removed; 5 previous and 0 current paragraphs rearranged.
Tables are not compared: 3 previous and 2 current tables excluded. Dates, whitespace, punctuation and numbering changes are ignored; changes to financial figures remain significant.
A changed paragraph is not evidence that risk increased or decreased. An unchanged paragraph does not establish that risk stayed the same.
Added paragraphs (10)
Current report
WEED, Inc. (the “Company”) is a multi-national bio-pharmaceutical and real estate holding company. Our mission is to lead the development and application of cannabis-derived compounds for medical and industrial use. During fiscal 2025, the Company focused on asset preservation and the modernization of its business model, which included streamlining international operations and exploring the integration of blockchain and AI technologies within the regulated cannabis ecosystem.
Current report
Key Material Events of 2025
Current report
Research and Intellectual Property Development
Current report
The Company continues to integrate assets from the Hempirical Genetics, LLC acquisition. This includes a proprietary seedbank of over 250 cannabis and hemp strains, featuring rare Landrace varieties such as Panama Red and Acapulco Gold. Throughout 2025, management focused on cataloging these genetics to support future pharmaceutical research and consumer product strategies. These genetic assets are currently carried at a cost basis on our balance sheet, though management believes they represent significant long-term strategic value as the federal regulatory environment for cannabis evolves.
Current report
Strategic Technology Initiatives
Current report
In December 2025, the Company entered into a strategic partnership with Remergify, Inc. to evaluate the development of a digital asset ecosystem. This project aims to address banking and supply chain challenges through the potential launch of WEEDCoin and BUDZCoin. These initiatives are currently in the early development phase. The Company’s ability to successfully launch these digital assets is subject to the availability of capital and the complex, evolving regulatory framework governing digital assets and decentralized finance.
Current report
Real Estate Assets and Infrastructure
Current report
A cornerstone of the Company’s stability is its long-term real estate holdings. Management continues to maintain and market its high-value land assets, notably the "Four Winds of Lake Erie" property in Portland, New York. This 44-acre parcel, featuring significant lake frontage, represents a key "hard asset" that distinguishes the Company from peers in the microcap sector. These properties are held to provide the Company with a tangible asset base while management pursues its broader bio-pharmaceutical goals.
Current report
Licensing and Regulatory Compliance
Current report
Through its wholly-owned subsidiary, HEMP BioSciences Inc., the Company maintained its comprehensive suite of industrial hemp licenses in Arizona, including cultivation, nursery, and processing permits. Additionally, in late 2025, the Company successfully completed the de-registration of its non-essential international subsidiaries, WEED Hong Kong Ltd. and WEED Australia Ltd. This repatriation of assets and intellectual property to the U.S. parent company was a strategic move to reduce overhead and simplify the corporate governance structure.
Removed paragraphs (19)
Previous report
Currently, WEED and its subsidiaries are working on or planning for several different business opportunities in the cannabis & hemp field, including, but not limited to: both indoor and outdoor “grows”, cultivations & harvest for research, product development, processing and manufacturing of both Pharma & non-Pharma products, services, therapeutics, and treatments on a global basis for both the Medical Cannabis & Hemp (<.03 thc) global market space. Long terms goals include hopeful cures for many diseases and ailments for both man & animals utilizing the Cannabaceae plant and its derivatives. We will need additional financing to attempt to accomplish these goals.
Previous report
Second, on November 22, 2021, WEED completed the purchase of the Sugar Hill Golf course property located in the town of Portland, New York. WEED’s acquisition of this ~43 acre property with ~2000 ft. of Lake Erie waterfront also comes with the “unlimited water extractions rights” from Lake Erie related to the property, along with a complete wastewater management plant. WEED’s initial plan is to utilize the property to access the hemp and infused beverage markets as our property in the middle of the largest concord grape producing region of the United States. In the future, WEED may look to use the unique property infrastructure to build a luxury condos & resort development in the most natural settings to be ESG compliant in conjunction to WEEDs forming its Social Equity Advisory Council (SEAC) to create Diversity & Equality in our industry. This project is only in its conceptual stage, no funding or plans have been developed other than the proposed name: The Four Winds Luxury condos & resort to be “Cannabis Friendly” which would be a “FIRST” in the nation. The New York property is now owned by Four Winds of Lake Erie, LLC, a wholly-owned subsidiary of WEED, Inc.
Previous report
Third, WEED established WEED Australia Ltd. and it’s wholly owned Cannabis Institute of Australia (C.I.A.) in Australia in March of 2017, for the purpose of conducting cannabis and hemp research and potentially developing products and educational services in and for Australians as stated above. C.I.A. is a non-profit entity formed for the purpose of conducting cannabis and hemp research with universities and other non-profits to protect all intellectual rights, properties and usage in our highly regulated industry. The C.I.A. has the potential to develop products in Australia for domestic research and development of products, services and educational purposes to all seven States and territories, including Tasmania, to be marketed globally. WEED Australia is also our gateway to the Oceania & Asia emerging legal cannabis marketplace.
Previous report
Fourth, on May 2, 2022, we entered into a Share Exchange Agreement (the “Exchange Agreement”) with Hempirical Genetics, LLC, an Arizona limited liability company (“Hempirical”), under which we acquired all of the issued and outstanding membership interests of Hempirical from Jeffery Miller in exchange for $603,284 payable in Two Million (2,000,000) shares of our common stock (the “WEED Shares”), valued at $394,302 based on the value of our common stock, and $250,000 in cash to be paid over four years. With this acquisition, our newly acquired inventory includes over 200 High THC strains plus 15 “PURE” Landrace strains including Panama Red, Acapulco Gold, Red Bud Colombian, Santa Marta Gold, and ThaiSticks. Along with 30+ CBD & CBG strains. WEED believes that multiple combinations of precise cannabinoid strains will achieve the precise medical outcome desired.
Previous report
Corporate Overview
Previous report
We were originally incorporated under the name Plae, Inc., in the State of Arizona on August 20, 1999. At the time we operated under the name Plae, Inc., no business was conducted. No books or records were maintained and no meetings were held. In essence, nothing was done after incorporation until Glenn E. Martin took possession of Plae, Inc. in January 2005. On February 18, 2005, the corporate name was changed to King Mines, Inc. and then subsequently changed to its current name, United Mines, Inc., on March 30, 2005. No shares were issued until the Company became United Mines, Inc. From 2005 until 2015, we were an exploration stage mineral exploration company that owned a number of unpatented mining claims and Arizona State Land Department claims.
Previous report
On November 26, 2014, our Board of Directors approved the redomestication of our company from Arizona to Nevada (the “Articles of Domestication”), and approved Articles of Incorporation in Nevada, which differed from then-Articles of Incorporation in Arizona, primarily by (a) changing our name from United Mines, Inc. to WEED, Inc., (b) authorizing Twenty Million (20,000,000) shares of preferred stock, with blank check rights granted to our Board of Directors, and (c) authorizing Two Hundred Million (200,000,000) shares of common stock (the “Nevada Articles of Incorporation”). On December 19, 2014, the holders of a majority of our outstanding common stock approved the Articles of Domestication and the Nevada Articles of Incorporation at a Special Meeting of Shareholders. On January 16, 2015, the Articles of Domestication and the Nevada Articles of Incorporation went effective with the Secretary of State of the State of Nevada. On February 2, 2015, our name change to WEED, Inc., and a corresponding ticker symbol change to “BUDZ” went effective with FINRA and was reflected on the quotation of our common stock on OTC Markets.
Previous report
These changes were affected in order to make our corporate name and ticker symbol better align with our short-term and long-term business focus. Our current, short-term goals relate to the Cannabis Genomic Study and the resulting development of a variety of new cannabis strains, and, over the next 5 years, we plan to process those results in order to become an international cannabis research and product development company, with a globally-recognized brand focusing on building and purchasing labs, land and building commercial grade “Cultivation Centers” to consult, assist, manage & lease to universities, state governments, licensed dispensary owners and organic grow operators on a contract basis with a concentration on the legal and medical cannabis sector.
Previous report
Our long-term plan is to become a true “Seed-to-Sale” global holding company providing infrastructure, financial solutions, product development, and real estate options in this new emerging market. Our long term growth may also come from the acquisition of synergistic businesses, such as distilleries, to make anything from infused beverages to super oxygenated water with CBD and THC. Currently, we have formed WEED Australia Ltd., registered as an unlisted public company in Australia to address this Global demand. We have also formed WEED Israel Cannabis Ltd., an Israeli corporation, to address future global demand. We will look to conduct future research, marketing, import/exporting, and manufacturing of our proprietary products on an international level.
Previous report
On April 20, 2017, we entered into a Share Exchange Agreement with Sangre AT, LLC, a Wyoming limited liability company, under which we acquired all of the issued and outstanding limited liability company membership units of Sangre in exchange for Five Hundred Thousand (500,000) shares of our common stock, restricted in accordance with Rule 144. As a result of this agreement, Sangre is a wholly-owned subsidiary of WEED, Inc.
Previous report
Nine Months Ended September 30, 2025 Compared to Nine Months Ended September 30, 2024
Previous report
Results of Operations
Previous report
Operating Loss; Net Loss
Previous report
Revenue
Previous report
General and Administrative Expenses
Previous report
General and administrative expenses increased by $219,142, from $286,694 for the nine months ended September 30, 2024 to $505,836 for the nine months ended September 30, 2025, primarily due to increases in our consulting and services salary.
Previous report
Professional Fees
Previous report
Depreciation and Amortization
Previous report
Interest Expense
Reworded paragraphs (14)
Previous wording
Our first business opportunity was, and continues to be, through our wholly-owned subsidiary, Sangre AT, LLC (“Sangre”), where we are focused on the development and application of cannabis-derived compounds for the treatment of human disease and animal ailments. To that end Sangre, was working on a planned five-year Cannabis Genomic Study to complete a genetic blueprint of the Cannabis plant genus, by creating a global genomic classification of the entire plant. Sangre completed a 1-2 year Pilot Study in 2017 & 2018 at the University of Texas-Galveston thru Industrial Metagenomics at a cost of nearly $1 million USD. Sangre completed the pilot study with 30 cultivars from strains collected worldwide that included 30 strains (twenty-four female and six male). These results are highly proprietary and the basis of future studies to come. We need to raise additional funds to continue the next steps in our Cannabis Genomic Study and no work is being conducted now until further funds are available.
Current wording
Our first business opportunity was, and continues to be, through our wholly-owned subsidiary, Sangre AT, LLC (“Sangre”), where we are focused on the development and application of cannabis-derived compounds for the treatment of human disease and animal ailments. To that end Sangre, was working on a planned five-year Cannabis Genomic Study to complete a genetic blueprint of the Cannabis plant genus, by creating a global genomic classification of the entire plant. Sangre completed a 1-2 year Pilot Study in 2017 & 2018 at the University of Texas-Galveston through Industrial Metagenomics at a cost of nearly $1 million USD. Sangre completed the pilot study with 30 cultivars from strains collected worldwide that included 30 strains (twenty-four female and six male). These results are highly proprietary and the basis of future studies to come. We need to raise additional funds to continue the next steps in our Cannabis Genomic Study.
Previous wording
In conjunction with WEED Israel Cannabis Ltd., we made arrangements with Professor Elka Touitou to be available to be the head of WEEDs Israeli Advisory Board to lead and assist us with clinical trials in cannabis & hemp research studies in Israel. Professor Touitou was the Head of the Innovative Dermal, Transdermal and Transmucosal Delivery Lab at the Institute of Drug Research, The School of Pharmacy, HUJ, now retired but still has HUJ clinical trial & independent studies/lab privileges. Professor Touitou is an internationally renowned authority in the field of drug delivery and design of new technologies for efficient administration of drugs and development of new products. Professor Touitou has been involved in Cannabinoid research since 1988 at The Hebrew University of Jerusalem, (HUJ) Jerusalem, Israel. Previously, WEED was in the process of buying Professor Touitou’s various patents to include the bioavailability aspects of the cannabaceae plant. However, after expending over $500,000 USD to acquire the Professor Touitou’s patents, we had to terminate the agreement in 2019 due to the downturn of the Cannabis marketplace, and specifically as to public cannabis companies, which could not be resumed due to the Covid pandemic that was/is still ongoing globally. We have kept in constant contact with Professor Touitou thru our Managing Director of WEED Israel, Mr. Elliot Kwestel. As of 2022, Dr. Touitou still has interest in working with WEED to complete the purchase of her patents and begin clinical trials upon proper funding. WEED looks to achieve that funding through offerings of our securities.
Current wording
conjunction with WEED Israel Cannabis Ltd., we made arrangements with Professor Elka Touitou to be available to be the head of WEEDs Israeli Advisory Board to lead and assist us with clinical trials in cannabis & hemp research studies in Israel. Professor Touitou was the Head of the Innovative Dermal, Transdermal and Transmucosal Delivery Lab at the Institute of Drug Research, The School of Pharmacy, HUJ, now retired but still has HUJ clinical trial & independent studies/lab privileges. Professor Touitou is an internationally renowned authority in the field of drug delivery and design of new technologies for efficient administration of drugs and development of new products. Professor Touitou has been involved in Cannabinoid research since 1988 at The Hebrew University of Jerusalem, (HUJ) Jerusalem, Israel. Previously, WEED was in the process of buying Professor Touitou’s various patents to include the bioavailability aspects of the cannabaceae plant. However, after expending over $500,000 USD to acquire the Professor Touitou’s patents, we had to terminate the agreement in 2019 due to the downturn of the Cannabis marketplace, and specifically as to public cannabis companies, which could not be resumed due to the Covid pandemic that was/is still ongoing globally. We have kept in constant contact with Professor Touitou thru our Managing Director of WEED Israel, Mr. Elliot Kwestel. As of 2022, Dr. Touitou still has interest in working with WEED to complete the purchase of her patents and begin clinical trials upon proper funding. WEED looks to achieve that funding thru offerings of our securities.
Previous wording
Our comprehensive net loss decreased by $22,095, from $(96,044) to $(73,949), from the three months ended September 30, 2024, compared to the three months ended September 30, 2025. Our net operating loss decreased by $25,752 from $(92,649) to $(66,897) for the same period. The decrease in our comprehensive net loss and operating loss is primarily a result of decreases in general and administrative expenses and professional fees. These changes are detailed below.
Current wording
Our comprehensive net loss decreased by $265,124, from $(440,380) to $(175,256), from the three months ended March 31, 2026, compared to the three months ended March 31, 2025. Our net operating loss decreased by $270,782 from $(434,737) to $(163,955) for the same period. The decrease in our comprehensive net loss and operating loss is primarily a result of decreases in general and administrative expenses and professional fees. These changes are detailed below.
Previous wording
General and administrative expenses decreased by $6,314, from $64,833 for the three months ended September 30, 2024, to $58,519 for the three months ended September 30, 2025, primarily due to decreases in our consulting services and salary.
Current wording
General and administrative expenses decreased by $315,435, from $383,268 for the three months ended March 31, 2025, to $67,833 for the three months ended March 31, 2026, primarily due to decreases in our consulting services and salary.
Previous wording
Our professional fees decreased by $22,002 during the three months ended September 30, 2025, compared to the three months ended September 30, 2024. Our professional fees were $193 for the three months ended September 30, 2025, and $22,195 for the three months ended September 30, 2024. These fees are largely related to fees paid for legal and accounting services, along with compensation to independent contractors. We expect these fees to vary quarter-to-quarter as our business and stock price fluctuate if we continue to use stock-based compensation. In the event we undertake an unusual transaction, such as an acquisition, securities offering, or file a registration statement, we would expect these fees to substantially increase during that period.
Current wording
Our professional fees increased by $44,653 during the three months ended March 31, 2026, compared to the three months ended March 31, 2025. Our professional fees were $90,500 for the three months ended March 31, 2026, and $45,847 for the three months ended March 31, 2025. These fees are largely related to fees paid for legal and accounting services, along with compensation to independent contractors. We expect these fees to vary quarter-to-quarter as our business and stock price fluctuate if we continue to use stock-based compensation. In the event we undertake an unusual transaction, such as an acquisition, securities offering, or file a registration statement, we would expect these fees to substantially increase during that period.
Previous wording
During the three months ended September 30, 2025, we had depreciation and amortization expense of $8,185, compared to $5,621 in the three months ended September 30, 2024. Our depreciation and amortization expense primarily relates to our property and trademark acquisitions.
Current wording
During the three months ended March 31, 2026, we had depreciation and amortization expense of $5,622, compared to $5,622 in the three months ended March 31, 2025. Our depreciation and amortization expense primarily relates to our property and trademark acquisitions.
Previous wording
Interest expense increased from $(3,238) for the three months ended September 30, 2024, to $(7,016) for the three months ended September 30, 2025. Our interest expense primarily relates to notes payable from related parties.
Current wording
Interest expense increased from $(5,718) for the three months ended March 31, 2025, to $(14,099) for the three months ended March 31, 2026. Our interest expense primarily relates to notes payable from related parties.
Previous wording
During the nine months ended September 30, 2025, because of our operating losses, we did not generate positive operating cash flows. Our cash on hand as of September 30, 2025 was $400 and our monthly cash flow burn rate was approximately $53,000. We currently do not believe we will be able to satisfy our cash needs from our revenues for many years to come.
Current wording
During the three months ended March 31, 2026, because of our operating losses, we did not generate positive operating cash flows. Our cash on hand as of March 31, 2026 was $1,795 and our monthly cash flow burn rate was approximately $12,000. We currently do not believe we will be able to satisfy our cash needs from our revenues for many years to come.
Previous wording
Our total assets decreased by $206,099 as of September 30, 2025, as compared to December 31, 2024. The decrease in our total assets between the two periods was attributed primarily to decreases in cash.
Current wording
Our total assets decreased by $44,193 as of March 31, 2026 as compared to December 31, 2025. The decrease in our total assets between the two periods was attributed primarily to decreases in cash.
Previous wording
Our current liabilities and total liabilities increased by $91,974, as of September 30, 2025, as compared to December 31, 2024. This increase was primarily due to increases in accounts payable, related parties, and accrued officer compensation.
Current wording
Our current liabilities and total liabilities increased by $104,973, as of March 31, 2026, as compared to December 31, 2025. This increase was primarily due to increases in accounts payable, related parties, and accrued officer compensation.
Previous wording
We had cash available of $400 and $159,355 as of September 30, 2025 and December 31, 2024, respectively. Based on our lack of revenues, our cash on hand and current monthly burn rate of approximately $53,000, we will need to continue borrowing from our shareholders and other related parties, and/or raise money from the sales of our securities, to fund operations.
Current wording
We had cash available of $1,795 and $33,130 as of March 31, 2026 and December 31, 2025, respectively. Based on our lack of revenues, our cash on hand and current monthly burn rate of approximately $12,000, we will need to continue borrowing from our shareholders and other related parties, and/or raise money from the sales of our securities, to fund operations.
Previous wording
We had net cash used in operating activities of $75,471 for the nine months ended September 30, 2025, as compared to $288,079 for the nine months ended September 30, 2024. For the period in 2025, the net cash used in operating activities consisted primarily of our net loss of $(622,018), adjusted by depreciation and amortization of $16,865, debt discount amortization of $7,691, estimated fair value of stock based compensation and shares issued for services of $300,000 and $15,000, respectively, and accrued expenses of $152,499. For the period in 2024, the net cash used in operating activities consisted primarily of our net loss of $(377,492), adjusted by depreciation and amortization of $16,964, debt discount amortization of $7,691, estimated fair value of stock based compensation and shares issued for services of $20,000 and $14,000, respectively, and further adjusted by accrued expenses of $(17,829).
Current wording
We had net cash used in operating activities of $57,737 for the three months ended March 31, 2026, as compared to $71,838 for the three months ended March 31, 2025. For the period in 2026, the net cash used in operating activities consisted primarily of our net loss of $(175,256), adjusted by depreciation and amortization of $5,622, debt discount amortization of $2,564, estimated fair value of shares issued for services of $26,400 and imputed interest of $2,488, respectively, and accrued expenses of $73,412. For the period in 2025, the net cash used in operating activities consisted primarily of our net loss of $(440,455), adjusted by depreciation and amortization of $5,622, debt discount amortization of $2,563, estimated fair value of stock based compensation and shares issued for services of $300,000 and $15,000, respectively, and further adjusted by accrued expenses of $(44,456).
Previous wording
For the nine months ended September 30, 2025 and 2024, we had no cash flows provided from investing activities.
Current wording
For the three months ended March 31, 2026 and 2025, we had no cash flows provided from investing activities.
Previous wording
Our net cash used in financing activities for the nine months ended September 30, 2025, was $(82,300), compared to $3,925 for the nine months ended September 30, 2024. For the period in 2025, our financing activities related to proceeds of note payable of $47,000, an increase in due to officer of $700, offset by repayments of notes payable-related party of $(130,000). For the period in 2024, our financing activities related to proceeds of note payable of $10,000, an increase in due to officer of $8,925, offset by repayments of notes payable-related party of $(15,000).
Current wording
Our net cash used in financing activities for the three months ended March 31, 2026, was $(29,200), compared to $84,300 for the three months ended March 31, 2025. For the period in 2026, our financing activities related to proceeds of note payable of $30,000, offset by repayments of notes payable-related party of $(800). For the period in 2025, our financing activities related to proceeds of note payable of $45,700, offset by repayments of notes payable-related party of $(130,000).
Rearranged previous paragraphs (5)
Previous report — wording carried elsewhere
Our comprehensive net loss increased by $242,395, from $(378,436) to $(620,831), from the nine months ended September 30, 2024, compared to the nine months ended September 30, 2025. Our net operating loss increased by $198,275, from $(402,530) to $(600,805) for the same period. The increase in our comprehensive net loss and operating loss is primarily a result of increases in general and administrative expenses and professional fees. These changes are detailed below.
Previous report — wording carried elsewhere
We have not had any revenues since our inception. Once we have sufficient funding, we plan to research and possibly enter the hemp and infused beverage industry through our newly acquired property in New York, and conduct Sangre’s Cannabis Genomic Study and process those result. In the long-term we plan to be a company focused on purchasing land and building commercial grade “Cultivation Centers” to consult, assist, manage & lease to licensed dispensary owners and organic grow operators on a contract basis, with a concentration on the legal and medical marijuana (Cannabis) sector. Our long-term plan is to become a True “Seed-to-Sale” company providing infrastructure, financial solutions and real estate options in this new emerging market, worldwide. We plan to make our brand global and therefore we will look for opportunities to conduct future research, marketing, import and exporting, and manufacturing of any proprietary products on an international level.
Previous report — wording carried elsewhere
Our professional fees decreased by $28,459, from $98,872 for the nine months ended September 30, 2024 to $70,413 for the nine months ended September 30, 2025, primarily due to reduced consulting activities. These fees are largely related to fees paid for legal and accounting services, along with compensation to independent contractors, We expect these fees to vary quarter-to-quarter as our business and stock price fluctuate if we continue to use stock-based compensation. In the event we undertake an unusual transaction, such as an acquisition, securities offering, or file a registration statement, we would expect these fees to substantially increase during that period.
Previous report — wording carried elsewhere
During the nine months ended September 30, 2025 we had depreciation and amortization expense of $24,556, compared to $16,964 in the nine months ended September 30, 2024. Our depreciation and amortization expense primarily relates to our property and trademark acquisitions.
Previous report — wording carried elsewhere
Interest expense increased from $(9.563) for the nine months ended September 30, 2024 to $(21,180) for the nine months ended September 30, 2025. Our interest expense primarily relates to notes payable from related parties.